IFNB1 and COVID-19: The reasons for the age-associated differences in the early immune responses to SARS-CoV-2 require further study, but therapies that enhance these pathways may be an effective treatment strategy and help protect patients from severe outcomes, as suggested by ongoing trials of inhaled IFN-β1 for early treatment of COVID-19 (29).